AU2019323450B2 - Pyridinylmethylenepiperidine derivatives and uses thereof - Google Patents

Pyridinylmethylenepiperidine derivatives and uses thereof Download PDF

Info

Publication number
AU2019323450B2
AU2019323450B2 AU2019323450A AU2019323450A AU2019323450B2 AU 2019323450 B2 AU2019323450 B2 AU 2019323450B2 AU 2019323450 A AU2019323450 A AU 2019323450A AU 2019323450 A AU2019323450 A AU 2019323450A AU 2019323450 B2 AU2019323450 B2 AU 2019323450B2
Authority
AU
Australia
Prior art keywords
compound
mmol
alkyl
methyl
title compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019323450A
Other languages
English (en)
Other versions
AU2019323450A1 (en
Inventor
Chuanfei JIN
Yaping Xue
Wenhe ZHONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of AU2019323450A1 publication Critical patent/AU2019323450A1/en
Application granted granted Critical
Publication of AU2019323450B2 publication Critical patent/AU2019323450B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2019323450A 2018-08-24 2019-08-22 Pyridinylmethylenepiperidine derivatives and uses thereof Active AU2019323450B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810969837.5 2018-08-24
CN201810969837 2018-08-24
PCT/CN2019/101985 WO2020038435A1 (en) 2018-08-24 2019-08-22 Pyridinylmethylenepiperidine derivatives and uses thereof

Publications (2)

Publication Number Publication Date
AU2019323450A1 AU2019323450A1 (en) 2021-02-11
AU2019323450B2 true AU2019323450B2 (en) 2025-04-10

Family

ID=68437065

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019323450A Active AU2019323450B2 (en) 2018-08-24 2019-08-22 Pyridinylmethylenepiperidine derivatives and uses thereof

Country Status (7)

Country Link
US (1) US11858910B2 (https=)
EP (1) EP3841096A4 (https=)
JP (1) JP7405834B2 (https=)
CN (1) CN110437205B (https=)
AU (1) AU2019323450B2 (https=)
CA (1) CA3107145A1 (https=)
WO (1) WO2020038435A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111187252B (zh) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 吡啶酰基氮杂螺庚烷衍生物及其用途
CN111187251B (zh) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
CN114685443B (zh) * 2020-12-29 2023-07-18 广东东阳光药业有限公司 吡啶烯基哌啶衍生物的盐及其用途
CN114685440B (zh) * 2020-12-29 2023-07-18 广东东阳光药业有限公司 吡啶烯基哌啶衍生物的盐及其用途
US20240083870A1 (en) * 2020-12-29 2024-03-14 Sunshine Lake Pharma Co., Ltd. Salts of pyridinylmethylenepiperidine derivatives and uses thereof
CN114685441B (zh) * 2020-12-29 2023-07-18 广东东阳光药业有限公司 吡啶烯基哌啶衍生物的盐及其用途
CN114685444B (zh) * 2020-12-29 2023-07-18 广东东阳光药业有限公司 吡啶烯基哌啶衍生物的盐及其用途
CN112939952A (zh) * 2021-02-02 2021-06-11 深圳市第二人民医院(深圳市转化医学研究院) 一种3-羟基查尔酮衍生物及其用途
CN112898276A (zh) * 2021-02-02 2021-06-04 深圳市第二人民医院(深圳市转化医学研究院) 一种查尔酮衍生物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084949A1 (en) * 2002-03-29 2003-10-16 Eli Lilly And Company Pyridinoylpiperidines as 5-ht1f agonists
WO2004094380A1 (en) * 2003-04-18 2004-11-04 Eli Lilly And Company (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists
WO2005035499A1 (en) * 2003-09-12 2005-04-21 Eli Lilly And Company Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
WO2008047229A2 (en) * 2006-10-18 2008-04-24 Pfizer Products Inc. Biaryl ether urea compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
US6133290A (en) 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
DE602004008338T2 (de) 2003-12-17 2008-05-29 Eli Lilly And Co., Indianapolis Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten
CN101602708B (zh) * 2008-06-10 2012-11-21 江苏国华投资有限公司 芳烷醇哌啶衍生物及其在制备抗抑郁症药物中的应用
TW201028421A (en) 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
GB201114448D0 (en) 2011-08-22 2011-10-05 Takeda Pharmaceutical Compounds and their use
MX2016016488A (es) 2014-08-27 2017-03-30 Hoffmann La Roche Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar).
GB201416513D0 (en) * 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084949A1 (en) * 2002-03-29 2003-10-16 Eli Lilly And Company Pyridinoylpiperidines as 5-ht1f agonists
WO2004094380A1 (en) * 2003-04-18 2004-11-04 Eli Lilly And Company (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists
WO2005035499A1 (en) * 2003-09-12 2005-04-21 Eli Lilly And Company Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
WO2008047229A2 (en) * 2006-10-18 2008-04-24 Pfizer Products Inc. Biaryl ether urea compounds

Also Published As

Publication number Publication date
JP7405834B2 (ja) 2023-12-26
EP3841096A4 (en) 2022-05-18
CA3107145A1 (en) 2020-02-27
EP3841096A1 (en) 2021-06-30
WO2020038435A1 (en) 2020-02-27
US20210188803A1 (en) 2021-06-24
AU2019323450A1 (en) 2021-02-11
CN110437205B (zh) 2022-07-08
CN110437205A (zh) 2019-11-12
JP2021536433A (ja) 2021-12-27
US11858910B2 (en) 2024-01-02

Similar Documents

Publication Publication Date Title
AU2019323450B2 (en) Pyridinylmethylenepiperidine derivatives and uses thereof
US9714232B2 (en) Substituted piperazine compounds and methods of use thereof
EP3687989B1 (en) Substituted pyrimidine piperazine compound and use thereof
US10316025B2 (en) Substituted piperazine compounds and methods of use and use thereof
CN104163813B (zh) 取代的吲哚化合物及其使用方法和用途
CN111004214B (zh) 吡啶酰基哌啶衍生物及其用途
WO2015169180A1 (en) Substituted piperazine compounds and methods and use thereof
WO2020216152A1 (en) 8-substituted aryl vinyl xanthine derivatives and uses thereof
US10196383B2 (en) Substituted quinazoline compounds and preparation and uses thereof
CN110272425B (zh) 吡啶酰基八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN112300165B (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN109988170B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN111187252B (zh) 吡啶酰基氮杂螺庚烷衍生物及其用途
CN111187251B (zh) 吡啶酰基哌啶衍生物及其用途
CN109988169B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN110845402B (zh) 吡啶亚甲基哌嗪衍生物及其用途
WO2021097781A1 (zh) 吡啶亚甲基哌啶衍生物及其用途
CN109956945B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN118063445A (zh) 吡咯烷酰胺衍生物及其用途
CN118063444A (zh) 氮杂环丁烷酰胺衍生物及其用途
CN121627597A (zh) 取代的杂环化合物及其用途
HK40027192B (en) Substituted pyrimidine piperazine compound and use thereof
HK40027192A (en) Substituted pyrimidine piperazine compound and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)